###### Strengths and limitations of this study

-   This is the first study to evaluate the association between infertility treatments and intrauterine growth using multilevel analyses.

-   This was a single-centre study and requires further validation in the general population from a large-scale and multicentre cohort study.

-   Considering the characteristics of longitudinal estimated fetal weight at multiple prenatal check-ups throughout gestation, we performed multilevel analysis with a relatively large sample size.

-   Data on gestational weight gain, intake of alcohol and caffeine, antiphospholipid syndrome and socioeconomic status, which may affect intrauterine growth, were not considered in this study.

Background {#s1}
==========

Infertility is defined as a failure to conceive after 12 months of regular and unprotected sexual intercourse[@R1] and is estimated to affect one in six couples globally. Treatments available for infertility include ovulation induction with timed intercourse, artificial insemination, in vitro fertilisation (IVF) and intracytoplasmic sperm injection.[@R1]

Embryo transfer during IVF or intracytoplasmic sperm injection (called assisted reproductive technology (ART) procedures) can be performed using either fresh-thawed or frozen-thawed embryos. Recently, the number of infants born from frozen embryo transfer (FET) has increased compared with those born from fresh-embryo transfer techniques.[@R2]

Several recent studies report an association between birth weight and infertility treatment. For example, ovulation induction and fresh-embryo transfer are associated with an increased risk of small-for-gestational-age and lower birth weight compared with spontaneous conception.[@R5] As the use of FET is going to increase in the future, it is important to examine the association between FET and fetal growth. Several studies suggest that FET is associated with a higher birth weight than spontaneous, fresh-embryo transfer and non-ART conceptions,[@R6] as well as with large-for-gestational-age neonates.[@R9]

Knowledge about when and how infertility treatment affects fetal growth might help predict its effect. This might also help us better understand the short-term and long-term prognoses of infertility treatments.[@R12] However, to the best of our knowledge, there is no study that has evaluated the effect of various infertility treatments, including FET, on intrauterine growth in detail. Although previous studies report the role of perinatal factors on birth weight, we also explored their role in the trajectory of fetal growth because the effect might be different depending on the stage of pregnancy.

The present study has the following aims; (1) to identify differences in intrauterine growth according to infertility treatment compared with spontaneous conception and (2) to describe intrauterine growth trajectories following different methods of conception by using multi-level models that might be appropriate for statistical analysis using repeated longitudinal measures data in the same individual.

Methods {#s2}
=======

Study design and population {#s2-1}
---------------------------

This retrospective cohort study was conducted at the University of Yamanashi Hospital. The study population comprised of singleton pregnant women who underwent prenatal check-ups and delivered at the University of Yamanashi Hospital between 1 July 2012 and 30 September 2017. Prenatal check-ups and ultrasound examinations were conducted according to the following schedule; once a month from 12 to 23 weeks, every 2 weeks from 24 to 35 weeks, once a week from 36 to 39 weeks and twice a week after 40 weeks.[@R13] The pregnant women who were hospitalised for various reasons, such as hypertensive disorders of pregnancy (HDP), placenta previa, gestational diabetes mellitus (GDM) and threatened preterm labour, had prenatal check-ups and ultrasound examinations once a week or more, regardless of the hospitalisation period.

This study was initiated in July 2018. Based on the national ethical guidelines, we have published information on the conduct and purpose of this research on the university's website. Moreover, we have ensured rejection opportunities wherever possible through the university's website. However, none of the patients denied their participation.

Data collection {#s2-2}
---------------

Data on baseline demographics, infertility treatment and medical and family history were collected from medical records. The data selected included maternal age at delivery, parity, gestational period, HDP, GDM, pregestational weight status, placenta previa, thyroid disease and smoking status. Most of these factors have been previously described as potential confounding factors for intrauterine growth.[@R13] Type of infertility treatment was subdivided into spontaneous conception, infertility treatment without ART, fresh-embryo transfer and FET. Infertility treatment without ART included stimulating ovulation with fertility drugs and intrauterine insemination.

HDP was defined as blood pressure ≥140/90 mm Hg on at least two occasions during pregnancy.[@R13] Prepregnancy body mass index (BMI) was calculated according to the WHO standards (body weight (kg)/height (m)^2^). We classified the participants as being underweight (BMI \<18.5 kg/m^2^), normal (BMI 18.5--25.0 kg/m^2^), or overweight (BMI ≥25.0 kg/m^2^) in accordance with the WHO classification of BMI.[@R19] We categorised maternal age as \<25, 25--34, or ≥35 years. GDM was diagnosed if there was ≥1 abnormal plasma glucose value (≥92, 180 and 153 mg/dL for fasting, 1-hour and 2-hour plasma glucose concentrations, respectively) after a 75-gram oral glucose tolerance test.[@R13] Placenta previa was defined as the presence of placental tissue that extended over the internal cervical os.[@R21] Thyroid disease was defined as Basedow disease or hypothyroidism (serum thyroid-stimulating hormone (TSH) concentrations\>2.5 mIU/L in the first trimester and \>3 mIU/L in the second trimester).[@R22] Smoking status was ascertained at the first visit and we divided the participants into two groups: smoking and non-smoking. The gestational age was determined based on the last menstrual period. Moreover, gestational age according to fresh-embryo transfer was calculated from the day of oocyte retrieval, which was converted into menstrual age by adding 14 days. Hormone-supplemented cycle FET was performed 5 days after the administration of progesterone vaginal tablets, and the actual gestational age was calculated by adding 14 days to the date when these tablets were used for the first time. On the contrary, natural cycle FET was performed 3 days after ovulation, and the actual gestational age was calculated by adding 14 days to the ovulation date. Since there were cases introduced from other hospitals due to perinatal complications or as per patient's will, the gestational age was confirmed by ultrasonography in all cases. We calculated the estimated fetal weight (EFW) at each prenatal check-up using the Shinozuka technique, which is commonly used in Japan.[@R23] The formula is as follows: EFW (g)=1.07 × BPD^3^ +3.00 × 10^−1^AC^2^×FL, where BPD stands for biparietal diameter (cm), AC stands for abdominal circumference (cm) and FL stands for femur length (cm).[@R23]

We used EFW to estimate intrauterine growth since BPD, AC and FL do not accurately reflect intrauterine growth. For example, the association between BPD and fetal growth restriction was rarely observed.[@R24] In contrast, AC was the primary parameter associated with impaired intrauterine growth.[@R24] This phenomenon may reflect the brain-sparing effect due to endothelial dysfunction. Fetal growth restriction is most commonly caused by placental insufficiency. In response, the fetus adapts its circulation to preserve oxygen and nutrient supply to the brain (brain-sparing).[@R25] We divided the gestational duration (days) into eight periods because there may be differences in the effects of infertility treatment on intrauterine growth during each period of pregnancy. We built a model equation to consider the difference. The periods were as follows; period 1 (98--104 days), period 2 (105--132 days), period 3 (133--160 days), period 4 (161--188 days), period 5 (189--216 days), period 6 (217--244 days), period 7 (245--272 days) and period 8 (≥273 days).

Statistical analysis {#s2-3}
--------------------

Linear mixed-effects regression analysis (random intercepts and slopes model) was conducted to determine the estimates of slopes in each gestational period by infertility treatment since repeated measurement results were used. There are several reasons why this multilevel analysis is helpful for analysis using repeatedly measured data. First, unlike other traditional statistical models, multilevel analysis can handle correlated longitudinal data within an individual level as a nested structure.[@R26] Second, time can be treated as a continuous variable in multilevel analysis. Thus, unbalanced data and unequal spacing conditions can be flexibly handled under multilevel analysis through the adequate specification of the time predictor.[@R26] Finally, although missing data can arise for many reasons in longitudinal research (ie, missed appointments, participant incapacity, dropout, or lost follow-up), missing data can be handled flexibly in the multilevel analysis.[@R26] The first level represented repeated measurements clustered within individuals, and the second level was the individual level. As in previous studies,[@R19] we constructed the following model to evaluate differences in the intercepts and slopes for each interval between the gestational periods:

EFW~*i*t~ =*β*~1~+*β*~2~\*X~1*it*~+*β*~3~\*X~2~+ *β*~4~\*X~2~\*X~1*it*~+*β*~5~\*X~3~+*β*~6~\*X~3~\*X~1*it*~+ *β*~7~\*X~4~+*β*~8~\*X~4~\*X~1*it*~+*β*~9~\*X~5~+*β*~10~\*X~5~\* X~1*it*~+*β*~11~\*X~6~+*β*~12~\*X~6~\* X~1*it*~+*β*~13~\*X~7~+*β*~14~\*X~7~\* X~1*it*~+*β*~15~\*X~8~+*β*~16~\*X~8~\*X~1*it*~+*β*~17~\*X~9~+*β*~18~\*X~9~\*X~1*it*~+*β*~19~\*X~10~+*β*~20~\* X~10~\*X~1*it*~+*β*~21~\*X~11~+*β*~22~\*X~11~\*X~1*it*~+*e*~*it*~+*b*~1*i*~+*b*~2*i*~\*X~1*it*~

where *i* represents the individual, *t* represents time, *β1--22* represent the regression coefficient of the fixed effect and *e* is the error term. (X~1~, gestational duration; X~2~, gestational period; X~3~, multiparity; X~4~, HDP; X~5~, infertility treatment type; X~6~, maternal age group; X~7~, smoking status; X~8~, placenta previa; X~9~, Basedow disease; X~10~, hypothyroidism; X~11~, GDM).

We describe the reference intrauterine growth trajectories for each infertility treatment group (25--34 years old, nulliparity, normal prepregnancy BMI, non-smoking, no pregnancy complications) after controlling for pregnancy complications (HDP, GDM, placenta previa, Basedow disease and hypothyroidism) and factors affecting intrauterine growth (gestational duration, smoking, parity, maternal age and prepregnancy BMI) to better understand the results of the multilevel analysis.

We used the estimated value of the reference group (ie, estimated values are all zero) to describe growth trajectories, with the exception of infertility treatment. The estimated intercept and slope of each gestational period was calculated from the results of the multilevel analysis. Then, the estimated lines of each period were described using EFW at each gestational week, which was calculated based on these values.

All analyses were performed using IBM SPSS Statistics V.25 and SAS V.9.4.

Patient and public involvement {#s2-4}
------------------------------

Patients were not invited to comment on the study design and were not consulted to develop patient-relevant outcomes or interpret the results.

Results {#s3}
=======

Maternal background {#s3-1}
-------------------

Among 2583 pregnant women who underwent prenatal check-ups during the study period and delivered at \>22 weeks gestation (excluding stillbirth), women with twin pregnancies (n=38) and with missing obstetric information (n =158) were excluded. To increase the homogeneity of our study population, we also excluded patients with a chromosomal abnormality (n = 10). Finally, 37 239 prenatal examination results from 2377 pregnant women (average 15.6 examinations per woman, 1196 male fetuses (50.3%)) were included for the final multilevel analysis model. Patients were divided into the following four groups: spontaneously conceived (n=1764), infertility treatment without ART (n=171), fresh-embryo transfer (n=112) and FET (n=330). In this study, we used the spontaneously conceived group as the reference group.

The mean maternal age was 32.58±5.12 years, and 1250 (52.6%) women were nulliparous, and the mean pre-pregnancy BMI was 21.42±3.73 kg/m^2^. [Table 1](#T1){ref-type="table"} lists the clinical characteristics of the study population.

###### 

Maternal background characteristics in FET, fresh-embryo transfer, infertility treatment without ART and spontaneously conceived groups

  Characteristics of the women   FET group (n=330)   Fresh-embryo transfer group (n=112)   Infertility treatment without ART group (n=171)   Spontaneously conceived group (n=1764)   P value
  ------------------------------ ------------------- ------------------------------------- ------------------------------------------------- ---------------------------------------- ---------
  Maternal age (years)           35.92±3.84          36.00±3.95                            34.33±4.28                                        31.57±5.07                               \<0.001
  Gestational period (days)      270.68±20.17        269.39±16.77                          270.99±15.70                                      269.65±20.08                             0.71
  Birth weight (g)               3063.34±500.77      2882.30±393.12                        3035.82±472.20                                    2975.84±494.86                           \<0.001
  Intrapartum haemorrhage (g)    898.17±738.95       602.47±428.90                         669.61±612.61                                     584.14±441.80                            \<0.001
  Prepregnancy BMI (kg/m^2^)     21.34±2.77          21.07±2.93                            21.63±3.30                                        21.44±3.97                               0.64
  Nulliparity                    223 (67.5)          86 (76.8)                             113 (66.1)                                        828 (46.9)                               \<0.001
  Caesarean section              122 (36.9)          29 (25.9)                             50 (29.2)                                         498 (28.2)                               0.03
  HDP                            21 (6.4)            6 (5.4)                               10 (5.8)                                          56 (3.2)                                 0.03
  GDM                            4 (1.2)             0 (0.0)                               1 (0.6)                                           48 (2.7)                                 0.04
  Previa placenta                2 (0.6)             1 (0.9)                               2 (1.2)                                           18 (1.0)                                 0.90
  Basedow disease                6 (1.8)             2 (1.8)                               3 (1.8)                                           17 (0.9)                                 0.44
  Hypothyroidism                 14 (4.2)            4 (3.6)                               7 (4.1)                                           35 (2.0)                                 0.04
  Smoking during pregnancy       2 (0.6)             0 (0.0)                               2 (1.2)                                           40 (2.3)                                 0.07
  Family history of HT           91 (27.6)           30 (26.8)                             52 (30.4)                                         355 (20.1)                               \<0.001
  Family history of DM           78 (23.6)           21 (18.8)                             42 (24.6)                                         278 (15.8)                               \<0.001

Values are presented as average ±SD or number (%).

ART, assisted reproductive technology; BMI, body mass index; DM, diabetes mellitus; FET, frozen embryo transfer; GDM, gestational diabetes mellitus; HDP, hypertensive disorders of pregnancy; HT, hypertension.

There were differences in maternal age, birth weight, intrapartum haemorrhage, nulliparity, caesarean section, HDP, GDM, hypothyroidism, family history of hypertension and family history of diabetes mellitus in the four groups.

Solutions for fixed effects of intrauterine growth analyses and intrauterine growth trajectories of male fetuses {#s3-2}
----------------------------------------------------------------------------------------------------------------

Solutions for the fixed effects of intrauterine growth analyses are presented in [table 2](#T2){ref-type="table"}. For the effect of infertility treatment as a primary outcome, only the interaction between infertility treatment (FET) and gestation duration (estimate: 0.36; 95% CI: 0.06 to 0.67) significantly affected the intrauterine growth of male fetuses. The association between additional factors and male intrauterine growth was also investigated. The following factors significantly affected the intrauterine growth of male fetuses; multiparity (estimate: −35.71; 95% CI: −65.63 to −5.80), interaction between multiparity and gestation duration (estimate: 0.23; 95% CI: 0.02 to 0.44), HDP (estimate: 82.22; 95% CI: 8.49 to 155.96), interaction between HDP and gestation duration (estimate: −0.56; 95% CI: −1.06 to 0.064), prepregnancy BMI (underweight) (estimate: 78.91; 95% CI: 38.09 to 119.73), prepregnancy BMI (overweight) (estimate: −79.45; 95% CI: −122.21 to −36.69), interaction between prepregnancy BMI (underweight) and gestation duration (estimate: −0.53; 95% CI: −0.81 to −0.24), interaction between prepregnancy BMI (overweight) and gestation duration (estimate: 0.48; 95% CI: 0.18 to 0.77), and GDM (estimate: −111.30; 95% CI: −195.63 to −26.95).

###### 

Solutions for fixed effects for estimated fetal weight based on the multivariate regression model after controlling for gestational duration, maternal age, parity, infertility treatment, prepregnancy BMI, smoking status, pregnancy complications and their interaction in male neonates

  Factor                                                     Male                   
  ---------------------------------------------------------- ---------- ----------- -----------
  Intercept                                                  −674.94    432.7       0.12
  Gestational duration                                       7.48       4.29        0.08
  Period                                                                            \<0.0001
   Period 1                                                  0          Reference   Reference
   Period 2                                                  78.56      435.27      0.87
   Period 3                                                  −553.07    435.59      0.2
   Period 4                                                  −1540.12   435.16      0.0004
   Period 5                                                  −2417.04   435.42      \<0.0001
   Period 6                                                  −2818.34   435.84      \<0.0001
   Period 7                                                  −2704.81   436.13      \<0.0001
   Period 8                                                  −2425.97   473.7       \<0.0001
  Period\*gestational duration                                                      \<0.0001
   Period 1\*gestational duration                            0          Reference   Reference
   Period 2\*gestational duration                            −1.15      4.31        0.79
   Period 3\*gestational duration                            3.61       4.30        0.40
   Period 4\*gestational duration                            9.71       4.30        0.02
   Period 5\*gestational duration                            14.37      4.30        0.0008
   Period 6\*gestational duration                            16.23      4.30        0.0002
   Period 7\*gestational duration                            15.8       4.29        0.0002
   Period 8\*gestational duration                            14.73      4.34        0.0007
  Multiparity                                                −35.71     15.26       0.02
  Multiparity\*gestational duration                          0.23       0.11        0.03
  HDP                                                        82.22      37.62       0.03
  HDP\*gestational duration                                  −0.56      0.26        0.03
  Infertility treatment                                                             0.03
   Spontaneously conceived                                   0          Reference   Reference
   Infertility treatment without ART                         123.63     65.32       0.06
   Fresh-embryo transfer                                     55.89      42.08       0.18
   FET                                                       −34.54     22.2        0.12
  Infertility treatment\*gestational duration                                       0.01
   Spontaneously conceived\*gestational duration             0          Reference   Reference
   Infertility treatment without ART\*gestational duration   −0.84      0.46        0.07
   Fresh-embryo transfer\*gestational duration               −0.28      0.29        0.33
   FET\*gestational duration                                 0.36       0.16        0.02
  Maternal age                                                                      0.9
   25--34                                                    0          Reference   Reference
   ＜25                                                      14.11      32.55       0.66
   ≥35                                                       −1.34      16.05       0.93
  Maternal age\*gestational duration                                                0.44
   25--34\*gestational duration                              0          Reference   Reference
   \<25 years\*gestational duration                          −0.28      0.22        0.22
   ≥35 years\*gestational duration                           0.019      0.11        0.87
  Prepregnancy BMI                                                                  \<0.0001
   Normal                                                    0          Reference   Reference
   Underweight                                               78.91      20.82       0.0002
   Overweight                                                −79.45     21.81       0.0003
  Prepregnancy BMI\*gestational duration                                            \<0.0001
   Normal\*gestational duration                              0          Reference   Reference
   Underweight\*gestational duration                         −0.53      0.14        0.0003
   Overweight\*gestational duration                          0.48       0.15        0.0017
  Smoking                                                    79.61      53.17       0.13
  Smoking\*gestational duration                              −0.45      0.37        0.22
  Previa placenta                                            26.86      83.71       0.75
  Previa placenta\*gestational duration                      −0.12      0.52        0.82
  Basedow disease                                            −88.79     65.62       0.18
  Basedow disease\*gestational duration                      0.74       0.45        0.1
  Hypothyroidism                                             −24.37     45.67       0.59
  Hypothyroidism\*gestational duration                       0.23       0.32        0.47
  GDM                                                        −111.3     43.02       0.0097
  GDM\*gestational duration                                  0.87       0.3         0.0042

ART, assisted reproductive technology; BMI, body mass index; FET, frozen embryo transfer; GDM, gestational diabetes mellitus; HDP, hypertensive disorders of pregnancy.

The intrauterine growth trajectories of male fetuses are shown in [figure 1](#F1){ref-type="fig"}. It can be presumed that there was little difference in the intrauterine growth during the first trimester in all groups, and only the FET group showed more intrauterine growth compared with the reference group from the second trimester to term. EFW calculated at 37 weeks was 2650 g in the reference group and 2709 g in the FET group.

![Intrauterine growth estimated trajectories and estimated fetal weight at each gestational week depending on the type of infertility treatment of male fetuses. These trajectories are described using the estimated value of the reference group except for the type of infertility treatment (25--34 years old, nulliparity, normal prepregnancy BMI, non-smoking, no pregnancy complications). ART, assisted reproductive technology; BMI, body mass index; FET, frozen embryo transfer](bmjopen-2019-033675f01){#F1}

Solutions for fixed effects of intrauterine growth analyses and intrauterine growth trajectories of female fetuses {#s3-3}
------------------------------------------------------------------------------------------------------------------

Solutions for the fixed effects of intrauterine growth analyses are presented in [table 3](#T3){ref-type="table"}. We found that infertility treatment (FET) (estimate: −69.85; 95% CI: −112.09 to −27.61) and the interaction between infertility treatment (FET) and gestation duration (estimate: 0.57; 95% CI: 0.28 to 0.87) significantly affected intrauterine growth of the female fetus. The following factors significantly affected the intrauterine growth of female fetuses; prepregnancy BMI (underweight) (estimate: 85.50; 95% CI: 47.96 to 123.05), interaction between prepregnancy BMI (underweight) and gestational duration (estimate: −0.57; 95% CI: −0.82 to −0.31), Basedow disease (estimate: 120.76; 95% CI: 5.08 to 236.43), interaction between Basedow disease and gestation duration (estimate: −0.85; 95% CI: −1.65 to −0.05), and GDM (estimate: −170.01; 95% CI: −270.01 to −70.00).

###### 

Solutions for fixed effects for estimated fetal weight based on the multivariate regression model after controlling for gestational duration, maternal age, parity, infertility treatment, prepregnancy BMI, smoking status, pregnancy complications and their interaction in female neonates

  Factor                                                     Female                 
  ---------------------------------------------------------- ---------- ----------- -----------
                                                             Estimate   SE          P value
  Intercept                                                  −160.67    460.53      0.73
  Gestational duration                                       2.21       4.55        0.63
  Period                                                                            \<0.0001
   Period 1                                                  0          Reference   Reference
   Period 2                                                  −419.29    463.13      0.37
   Period 3                                                  −1004.82   463.49      0.03
   Period 4                                                  −2020.79   463.03      \<0.0001
   Period 5                                                  −2922.03   463.28      \<0.0001
   Period 6                                                  −3485.55   463.82      \<0.0001
   Period 7                                                  −3199.34   463.51      \<0.0001
   Period 8                                                  −2883.19   496.27      \<0.0001
  Period\*gestational duration                                                      \<0.0001
   Period 1\*gestational duration                            0          Reference   Reference
   Period 2\*gestational duration                            3.91       4.57        0.39
   Period 3\*gestational duration                            8.32       4.56        0.07
   Period 4\*gestational duration                            14.63      4.55        0.0013
   Period 5\*gestational duration                            19.41      4.55        \<0.0001
   Period 6\*gestational duration                            22.03      4.55        \<0.0001
   Period 7\*gestational duration                            20.86      4.55        \<0.0001
   Period 8\*gestational duration                            19.65      4.59        \<0.0001
  Multiparity                                                −16.27     14.47       0.26
  Multiparity\*gestational duration                          0.07       0.099       0.48
  HDP                                                        43.1       41.43       0.3
  HDP\*gestational duration                                  −0.23      0.28        0.43
  Infertility treatment                                                             0.0049
   Spontaneously conceived                                   0          Reference   Reference
   Infertility treatment without ART                         65.48      63.56       0.3
   Fresh-embryo transfer                                     17.67      37.45       0.64
   FET                                                       −69.85     21.54       0.0012
  Infertility treatment\*gestational duration                                       0.0007
   Spontaneously conceived\*gestational duration             0          Reference   Reference
   Infertility treatment without ART\*gestational duration   −0.30      0.44        0.49
   Fresh-embryo transfer\*gestational duration               −0.18      0.26        0.48
   FET\*gestational duration                                 0.57       0.15        0.0001
  Maternal age                                                                      0.34
   25--34                                                    0          Reference   Reference
   ＜25                                                      −44.82     30.47       0.14
   ≥35                                                       −5.77      15.35       0.71
  Maternal age\*gestational duration                                                0.46
   25--34\*gestational duration                              0          Reference   Reference
   \<25 years\*gestational duration                          0.21       0.21        0.32
   ≥35 years\*gestational duration                           0.1        0.11        0.37
  Prepregnancy BMI                                                                  \<0.0001
   Normal                                                    0          Reference   Reference
   Underweight                                               85.5       19.15       \<0.0001
   Overweight                                                −39.71     21.69       0.07
  Prepregnancy BMI\*gestational duration                                            \<0.0001
   Normal\*gestational duration                              0          Reference   Reference
   Underweight\*gestational duration                         −0.57      0.13        \<0.0001
   Overweight\*gestational duration                          0.25       0.15        0.1
  Smoking                                                    −16.03     47.73       0.74
  Smoking\*gestational duration                              0.12       0.33        0.71
  Previa placenta                                            187.04     176.06      0.29
  Previa placenta\*gestational duration                      −1.17      0.93        0.21
  Basedow disease                                            120.76     59.01       0.04
  Basedow disease\*gestational duration                      −0.85      0.41        0.04
  Hypothyroidism                                             −7.99      39.23       0.84
  Hypothyroidism\*gestational duration                       0.095      0.27        0.73
  GDM                                                        −170.01    51.01       0.0009
  GDM\*gestational duration                                  1.09       0.35        0.0022

ART, assisted reproductive technology; BMI, body mass index; FET, frozen embryo transfer; GDM, gestational diabetes mellitus; HDP, hypertensive disorders of pregnancy.

The intrauterine growth trajectories are shown in [figure 2](#F2){ref-type="fig"}. Similar to male fetuses, it can be presumed that there is a slight difference in the intrauterine growth in the first trimester in all groups and only the FET group showed more intrauterine growth than the reference group from the second trimester to term. This difference was more significant in female than in male fetuses. The EFW calculated at 37 weeks was 2614 g in the reference group and 2693 g in the FET group.

![Intrauterine growth estimated trajectories and estimated fetal weight at each gestational week depending on the type of infertility treatment of female fetuses. These trajectories are described using the estimated value of the reference group except for the type of infertility treatment (25--34 years old, nulliparity, normal prepregnancy BMI, non-smoking, no pregnancy complications). ART, assisted reproductive technology; BMI, body mass index; FET, frozen embryo transfer.](bmjopen-2019-033675f02){#F2}

Discussion {#s4}
==========

This study evaluated the association between infertility treatment and intrauterine growth using multilevel analyses and described intrauterine growth trajectories using EFW. In both sexes, only the FET group gained more intrauterine growth than the spontaneously conceived group from the second trimester to term. This difference was particularly significant in female fetuses.

To the best of our knowledge, this is the first study to evaluate the association between infertility treatment and intrauterine growth using multilevel analyses of longitudinal EFW data obtained at prenatal check-ups in Japanese patients.

Our result was consistent with that of a previous study, which showed that FET was associated with birth weights 192 g higher than those for spontaneously conceived neonates.[@R8] In our multilevel model, the EFW at 40 weeks was estimated to be 90--124 g, 67--90 g and 110--179 g higher in the FET singletons than in fresh-embryo transfer singletons, spontaneously conceived singletons, and fertility treatment without ART singletons, respectively. This is due to the accumulation of growth differences between the FET group and other infertility treatment groups from the second trimester to term. There are several hypothetical mechanisms for the higher intrauterine growth rate seen after FET. First, the techniques of freezing and thawing enable the positive selection of high-quality embryos that survive the cryopreservation procedure. Therefore, it can be speculated that these embryos can also be more successful in other selective events, such as implantation, invasion and placentation or nutrition supplementation.[@R5] Second, FET performed in a natural cycle provides different conditions for embryo implantation and growth due to a different hormonal environment compared with the stimulated cycle.[@R5] We could not accurately obtain detailed information on hormonal treatment due to the retrospective design of our study. Therefore, we could not assess this effect. Finally, the cryopreservation technique can induce changes in the embryo at the epigenetic level.[@R30] Cryoprotectants affect DNA methylation and can provide protection against adverse effects on imprinting,[@R6] and the practice of culturing frozen embryos overnight before transfer on day 2 or 3 means a more advanced cleavage stage in comparison with fresh embryos.[@R6]

We also found possible sex differences in the association between intrauterine growth and FET with a significant association for the female sex. Only a few studies as of current date have focused on this association between intrauterine growth and sex differences with IVF pregnancies. O\'Neill *et al* reported that conception via IVF does not enhance sex-dependent growth differences.[@R31] This study by O\'Neill *et al* had certain limitations as compared with our study, such as relatively small sample size and no information on the difference between FET and fresh-embryo transfer. Conversely, Keane *et al* reported that the effect of FET birth weight was only significant for female infants.[@R32] The mechanisms leading to sex-dependent differences in intrauterine growth is not clear. One possible explanation could be that male and female neonates employ different mechanisms to cope with adverse environments or events, such as maternal asthma and pre-eclampsia.[@R31] The FET process introduces a number of potential stressors including freezing and thawing. Sex differences in response to these stresses may lead to a difference in intrauterine growth. Therefore, in this study, we analysed male and female fetuses separately. Further studies are required to better understand this relationship.

Our study has several strengths. We performed a multilevel analysis with a relatively large sample size considering the characteristics of longitudinal EFW at multiple prenatal check-ups throughout gestation. Most previous studies that focused on intrauterine growth used data from at most two or three prenatal check-ups and related birth weights.[@R35] In our study, we assessed intrauterine growth differences according to infertility treatment by adding a time-dependent covariate to the multilevel model.

This study has certain limitations. First, since it's a single-centre study, it might be difficult to extrapolate our results to the general population. The CI of the study results was relatively wide because of the small number of participants who received fertility treatment. Although we performed this multilevel analysis in a relatively large sample of pregnant women, it may be necessary to recruit more participants, especially by fertility treatment, to obtain appropriate results. A study based on population-based databases such as the ART database of the Japan Society of Obstetrics and Gynaecology would help confirm these results.[@R4] Second, data on other factors which may affect intrauterine growth, such as gestational weight gain, intake of alcohol and caffeine, antiphospholipid syndrome, differences in culture medium, pre-eclampsia, egg donation and socioeconomic status[@R13] could not be assessed accurately because of the retrospective nature of the study. Additionally, egg donation is not a common practice in Japan. Some participants in this study may have the aforementioned risk factors. There might be selection bias on the socio-economic status between each category in particular since ART in Japan is expensive and not covered by public health insurance. Third, smoking status and GDM information could be inaccurate. In comparison to previous studies,[@R41] this study might have underestimated maternal smoking and GDM because of several possible reasons. For instance, we used a questionnaire to ascertain maternal smoking status instead of using objective measurements. The smoking status was recorded as a dichotomous response, that is, 'smoking' included those participants who only answered 'smoking during pregnancy' and 'non-smoking' included those who answered 'have quit smoking', 'have never smoked', or 'no answer'. For unclear reasons, there were some missing data about GDM on the electronic record. However, data on other variables are likely to be relatively more accurate and objective compared with the previous studies.[@R43] GDM was significantly associated with intrauterine growth regardless of sex despite an underestimation of the incidence of GDM. While it is necessary to confirm the incidence of GDM in future studies, we believe that its underestimation in this study did not adversely affect the results. Fourth, the EFW used for the evaluation of intrauterine growth was not actual fetal weight; therefore, actual fetal growth might have been assessed inaccurately. However, previous studies that have evaluated the accuracy of sonographic fetal weight have reported high validity of ultrasonic estimation of fetal weight.[@R46] Barel *et al* reported that the Shinozuka technique used for evaluation of EFW in this study has a high coefﬁcient of correlation (0.91) between EFW and actual birth weight.[@R48] Therefore, we believe that EFW is an accurate measure of intrauterine growth that can reliably assess differences among the different types of infertility treatments. Finally, the longer the gestational period, the more likely it is that the fetus would be born via vaginal delivery or caesarean section. In other words, the number of EFW to be analysed decreases as it approaches the expected date of delivery. Thus, the possibility of a type II error might increase, especially in the third trimester. Although missing data can be handled flexibly in multilevel analysis, the results might have been influenced by missing values of EFW in the third trimester.

In summary, this study showed that intrauterine growth from the second trimester to term differs significantly between women who conceived via FET compared with those who conceived spontaneously. Considering the difference in intrauterine growth from the early stage in the FET group, the results support the mechanism for the higher intrauterine growth observed after FET (ie, positive selection for freezing). This difference was most notable in female fetuses. We believe that our research question is novel and will trigger further prospective research, both basic and clinical, to examine the effect of infertility treatment on fetal growth.
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